Skip to main content
SpringerLink
Log in

Optimality, Future and Terminal Costs: Comment on “Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran”

  • Letter to the Editor
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 09 February 2018

The Original Article was published on 09 August 2017

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ansaripour A, Uyl-de Groot CA, Redekop WK. Adjuvant Trastuzumab therapy for early HER2-positive breast cancer in Iran: a cost-effectiveness and scenario analysis for an optimal treatment strategy. PharmacoEconomics. 2018;36(1):91–103.

    Article  PubMed  Google Scholar 

  2. van Baal P, Meltzer D, Brouwer W, et al. Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to grima. PharmacoEconomics. 2013;31(5):369–73 (Discussion 375–6).

    Article  PubMed  Google Scholar 

  3. Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-effectiveness analysis alongside clinical trials II—an ISPOR good research practices task force report. Value Health. 2015;18(2):161–72.

    Article  PubMed  Google Scholar 

  4. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Industrial Engineering and Management, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel

    Noga Gershon & Yakir Berchenko

Authors
  1. Noga Gershon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yakir Berchenko
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yakir Berchenko.

Ethics declarations

Conflicts of interest

Noga Gershon and Yakir Berchenko declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gershon, N., Berchenko, Y. Optimality, Future and Terminal Costs: Comment on “Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran”. PharmacoEconomics 36, 383–384 (2018). https://doi.org/10.1007/s40273-018-0621-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-018-0621-x

Search

Navigation